ATE503770T1 - Humane monoklonale antikörper gegen hendra- und nipah-viren - Google Patents

Humane monoklonale antikörper gegen hendra- und nipah-viren

Info

Publication number
ATE503770T1
ATE503770T1 AT05858301T AT05858301T ATE503770T1 AT E503770 T1 ATE503770 T1 AT E503770T1 AT 05858301 T AT05858301 T AT 05858301T AT 05858301 T AT05858301 T AT 05858301T AT E503770 T1 ATE503770 T1 AT E503770T1
Authority
AT
Austria
Prior art keywords
antibodies
hendra
monoclonal antibodies
antibodies against
human monoclonal
Prior art date
Application number
AT05858301T
Other languages
English (en)
Inventor
Diviter Dimitrov
Zhongyu Zhu
Christopher Broder
Original Assignee
Us Gov Health & Human Serv
Jackson H M Found Military Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Jackson H M Found Military Med filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE503770T1 publication Critical patent/ATE503770T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1009—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05858301T 2005-03-14 2005-11-04 Humane monoklonale antikörper gegen hendra- und nipah-viren ATE503770T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66176605P 2005-03-14 2005-03-14
US67854705P 2005-05-05 2005-05-05
US71890205P 2005-09-20 2005-09-20
PCT/US2005/040050 WO2006137931A2 (en) 2005-03-14 2005-11-04 Human monoclonal antibodies against hendra and nipah viruses

Publications (1)

Publication Number Publication Date
ATE503770T1 true ATE503770T1 (de) 2011-04-15

Family

ID=37570906

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05858301T ATE503770T1 (de) 2005-03-14 2005-11-04 Humane monoklonale antikörper gegen hendra- und nipah-viren

Country Status (7)

Country Link
US (5) US7988971B2 (de)
EP (2) EP2336174B8 (de)
AT (1) ATE503770T1 (de)
AU (1) AU2005333155B2 (de)
DE (1) DE602005027258D1 (de)
ES (1) ES2546543T3 (de)
WO (1) WO2006137931A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP2495252B1 (de) * 2004-07-09 2018-04-18 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Lösliche Formen von Hendra- und Nipah-Virus-G-Glycoprotein
AU2005333155B2 (en) 2005-03-14 2011-11-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies against Hendra and Nipah viruses
US7858752B2 (en) * 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
AU2008275985B2 (en) * 2007-07-17 2013-09-19 E. R. Squibb & Sons, L.L.C. Monoclonal antibodies against Glypican-3
EP2303923B1 (de) * 2008-07-16 2015-06-24 Institute for Research in Biomedicine Das humane cytomegalovirus neutralisierende antikörper und anwendung davon
UA106354C2 (ru) 2008-07-16 2014-08-26 Инститьют Фо Рисерч Ин Байомедсин Антитела, нейтрализующие цитомегаловирус человека, и их применение
EP2596017B1 (de) 2010-07-22 2019-04-03 John W. Schrader Kreutz-schützender Antikörper gegen Influenzavirusinfektion
NZ624752A (en) * 2010-10-19 2015-11-27 Mayo Foundation Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
WO2012149536A1 (en) * 2011-04-28 2012-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Neutralizing antibodies to nipah and hendra virus
RU2681529C2 (ru) 2011-05-13 2019-03-07 Генри М. Джексон Фаундейшн Фор Дзе Эдвансмент Оф Милитари Медсин, Инк. Иммуногенные композиции гликопротеина g вирусов hendra и nipah
IN2014MN01781A (de) * 2012-02-08 2015-07-03 Igm Biosciences Inc
US9889192B2 (en) * 2012-10-01 2018-02-13 Thomas Jefferson University Immunization with rabies virus vector expressing foreign protein antigen
WO2014105849A1 (en) * 2012-12-28 2014-07-03 Xoma (Us) Llc Antibodies specific for fgfr4 and methods of use
SI2968520T1 (sl) 2013-03-14 2022-01-31 Macrogenics, Inc. Bispecifične molekule, ki so imunoreaktivne z imunskimi efektorskimi celicami, ki izražajo aktivacijski receptor
MX2016007870A (es) 2013-12-16 2016-10-07 Zoetis Services Llc Composiciones inmunogenas de glucoproteina g de los virus hendra y nipah.
CA2937866A1 (en) * 2014-01-24 2015-07-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Antibodies against f glycoprotein of hendra and nipah viruses
CN107108721B (zh) 2014-09-29 2021-09-07 杜克大学 包含hiv-1包膜靶向臂的双特异性分子
US20160319035A1 (en) * 2014-12-05 2016-11-03 Scott Kendall Dessain Pdk1 binding molecules and uses thereof
WO2018017996A1 (en) * 2016-07-22 2018-01-25 University Of Washington Identification and production of high affinity igm antibodies and derivatives thereof
CN111511398A (zh) 2017-12-20 2020-08-07 硕腾服务有限责任公司 针对亨德拉和尼帕病毒感染的疫苗
WO2019143884A1 (en) * 2018-01-19 2019-07-25 Vanderbilt University Conserved hiv antibody clonotypes and methods of use
CN110028579B (zh) * 2019-05-05 2020-12-18 中国人民解放军军事科学院军事医学研究院 一种抗尼帕病毒包膜糖蛋白的单克隆抗体及其应用
KR102264873B1 (ko) 2020-01-17 2021-06-14 대한민국(질병관리청장) 니파바이러스 g 당단백질에 특이적인 단클론 항체 및 이의 용도
EP4168029A1 (de) * 2020-06-19 2023-04-26 Board of Regents, The University of Texas System Gegen lange bst2-isoform gerichtete anti-bst2-antikörper
CN113968907B (zh) * 2020-07-22 2023-05-26 中国人民解放军军事科学院军事医学研究院 具有中和活性的抗尼帕病毒单克隆抗体及应用
CN113968908B (zh) * 2020-07-22 2023-03-14 中国人民解放军军事科学院军事医学研究院 具有广谱中和活性的抗亨尼帕病毒单克隆抗体及应用
WO2022177913A1 (en) * 2021-02-16 2022-08-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to mesothelin polypeptides
WO2023109844A1 (en) * 2021-12-14 2023-06-22 Doma Biopharmaceutical (Suzhou) Co., Ltd. Antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US661766A (en) 1899-11-07 1900-11-13 Carl J Mellin Piston-valve.
US678547A (en) 1901-05-31 1901-07-16 Seth S Crocker Fountain-pen.
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
WO2003057824A2 (en) 2001-11-13 2003-07-17 The Henry M. Jackson Foundation Compositions and methods for the inhibition of membrane fusion by paramyxoviruses
WO2005028673A1 (en) * 2003-09-22 2005-03-31 Institut Pasteur A method for detecting nipah virus and method for providing immunoprotection against henipaviruses
AU2005333155B2 (en) * 2005-03-14 2011-11-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies against Hendra and Nipah viruses

Also Published As

Publication number Publication date
US20090214428A1 (en) 2009-08-27
US8858938B2 (en) 2014-10-14
US20120064000A1 (en) 2012-03-15
EP2336174B1 (de) 2015-06-03
DE602005027258D1 (de) 2011-05-12
EP1861424B1 (de) 2011-03-30
EP2336174A2 (de) 2011-06-22
AU2005333155A1 (en) 2006-12-28
AU2005333155B2 (en) 2011-11-17
US7988971B2 (en) 2011-08-02
WO2006137931A2 (en) 2006-12-28
WO2006137931A3 (en) 2007-04-26
US20150071854A1 (en) 2015-03-12
US8313746B2 (en) 2012-11-20
EP2336174A3 (de) 2012-07-04
EP2336174B8 (de) 2015-09-23
US20140079715A1 (en) 2014-03-20
ES2546543T3 (es) 2015-09-24
EP1861424A2 (de) 2007-12-05
US20130149246A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
ATE503770T1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
EA202091710A1 (ru) Антитела против cd73 и способы их применения
NO20085362L (no) Hoyaffinitets humane og humaniserte anti-alfa5 beta1-integrin funksjonsblokkerende antistoffer med redusert immunogenisitet
NO20092285L (no) Humane, monoklonale antistoffer til BTLA og fremgangsmater for anvendelse
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
CY1124412T1 (el) Aνti-dkk-1 αντισωματα
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
EA201000424A1 (ru) Антитела к il-23
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
NO20081987L (no) Humane, monoklonale antistoffer mot CD70
NO20083053L (no) Humane monoklonale antistoffer mot O8E
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
EA201790330A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
UA109633C2 (uk) Антитіло людини проти тканинного фактора
NO20091387L (no) Antistoffer mot benmorfogene proteiner og reseptorer derav, fremgangsmater for deres anvendelse
EA201170205A1 (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
EA201200217A1 (ru) Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
NO20083793L (no) Antistoffer mot amyloid-beta peptid
NO20082167L (no) Anti-Myostatin-antistoffer
WO2009081285A3 (en) Hepatitis c virus antibodies
UA100682C2 (ru) АНТИТЕЛО, КОТОРОЕ НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ ЦИТОМЕГАЛОВИРУС (hCMV), И ЕГО ПРИМЕНЕНИЕ
ATE503769T1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
AU2012249274A8 (en) Neutralizing antibodies to Nipah and Hendra virus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties